• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrazines
• Natural Products and Extracts Plant Extracts Plant based Miscellaneous
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Introduction to Ligustrazine Hydrochloride (CAS No. 76494-51-4)

Ligustrazine Hydrochloride, with the chemical name (2E)-3-(4-hydroxyphenyl)-2-propen-1-one monohydrochloride, is a well-documented compound in the field of pharmaceutical chemistry. Its CAS number, 76494-51-4, uniquely identifies it in scientific literature and databases, underscoring its significance in both academic research and industrial applications. This compound has garnered considerable attention due to its pharmacological properties and potential therapeutic benefits, particularly in the realm of cardiovascular and neuroprotective treatments.

The chemical structure of Ligustrazine Hydrochloride features a chalcone moiety, which is a key pharmacophore responsible for its biological activity. The presence of a hydroxyl group on the phenyl ring and the conjugated system of the chalcone core contribute to its unique interaction with biological targets. This structural feature has been extensively studied in recent years, leading to a deeper understanding of its mechanism of action and therapeutic potential.

Recent research has highlighted the multifaceted pharmacological effects of Ligustrazine Hydrochloride. Studies have demonstrated its ability to exert vasodilatory effects by inhibiting the production of endothelin-1, a potent vasoconstrictor. Additionally, it has shown promise in protecting against ischemia-reperfusion injury in the brain and heart, making it a candidate for treating conditions such as stroke and myocardial infarction. The compound's ability to modulate nitric oxide synthase (NOS) activity has also been explored, suggesting its potential in managing cardiovascular diseases.

In clinical trials, Ligustrazine Hydrochloride has been evaluated for its efficacy in treating acute ischemic stroke. The results have been promising, with some studies indicating significant improvements in neurological function and reduced mortality rates among patients treated with this compound. These findings have prompted further investigation into its use as an adjunct therapy for stroke patients, particularly those who do not respond well to standard treatments.

The synthesis of Ligustrazine Hydrochloride is another area of active research. Chemists have developed several synthetic routes to produce this compound with high yield and purity. One such method involves the condensation of resorcinol with acetone, followed by hydrochlorination to yield the final product. These synthetic strategies are crucial for ensuring an adequate supply of Ligustrazine Hydrochloride for both research and clinical purposes.

The pharmacokinetics of Ligustrazine Hydrochloride have also been thoroughly investigated. Studies have shown that it exhibits rapid absorption after oral administration and reaches peak plasma concentrations within a few hours. The compound is metabolized primarily in the liver, with active metabolites contributing to its therapeutic effects. Understanding these metabolic pathways is essential for optimizing dosing regimens and minimizing potential side effects.

Future directions in the study of Ligustrazine Hydrochloride include exploring its potential role in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Preliminary studies suggest that it may protect against neurotoxicity by modulating inflammatory responses and antioxidant defenses in neural cells. These findings open up new avenues for therapeutic intervention and highlight the need for further preclinical and clinical investigations.

The regulatory landscape for Ligustrazine Hydrochloride is another critical aspect that influences its development and application. Regulatory agencies require rigorous testing to ensure safety and efficacy before approving a new drug or therapeutic agent. Compliance with these regulations is essential for bringing Ligustrazine Hydrochloride into clinical practice and making it available to patients who could benefit from its therapeutic properties.

Collaboration between academia, industry, and regulatory bodies plays a pivotal role in advancing the development of Ligustrazine Hydrochloride. Such partnerships facilitate knowledge sharing, accelerate research progress, and ensure that new therapies are developed efficiently and effectively. The collective efforts of these stakeholders are crucial for translating scientific discoveries into tangible benefits for patients worldwide.

In conclusion, Ligustrazine Hydrochloride (CAS No. 76494-51-4) is a promising compound with significant therapeutic potential in various medical conditions. Its unique chemical structure, multifaceted pharmacological effects, and positive clinical outcomes make it a subject of intense interest among researchers and clinicians alike. As further studies continue to uncover its benefits, Ligustrazine Hydrochloride is poised to play an increasingly important role in modern medicine.

• 76556-07-5(2,3,5,6-Tetramethylpyrazine trihydrate)
• 108-50-9(2,6-Dimethylpyrazine)
• 5910-89-4(2,3-Dimethylpyrazine)
• 14667-55-1(Trimethylpyrazine)
• 10-83-3(Color)
• 10-98-0(2-methyl Pyrazine)
• 25704-73-8(Pyrazine, dimethyl-)
• 1124-11-4(Ligustrazine)
• 109-08-0(2-Methylpyrazine)
• 123-32-0(2,5-Dimethylpyrazine)